Publication Name	World Journal of Gastroenterology
Manuscript ID	2554
Country	Cuba

Received	2013-02-28 16:35
Peer-Review Started	2013-04-03 11:49
To Make the First Decision	2013-05-14 19:00
Return for Revision	2013-05-27 10:48
Revised	2013-06-14 04:54
Second Decision	2013-07-12 16:45
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-07-13 01:02
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor	2013-11-28 17:06
Typeset the Manuscript	2013-12-25 16:48
Publish the Manuscript Online	2014-01-20 17:10

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Autobiography
Article Title	HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin
Manuscript Source	Invited Manuscript
All Author List	Yalena Amador-Cañizares, Gillian Martínez-Donato, Liz Álvarez-Lajonchere, Claudia Vasallo, Mariacarla Dausá, Daylen Aguilar-Noriega, Carmen Valenzuela, Ivette Raíces, Jean Dubuisson, Czeslaw Wychowski, Zurina Cinza-Estévez, Marlén Castellanos, Magdalys Núñez, Anny Armas, Yaimé González, Ismariley Revé, Ivis Guerra, Ángel Pérez Aguiar and Santiago Dueñas-Carrera
Funding Agency and Grant Number
Corresponding Author	Dr. Yalena Amador-Cañizares, Centro de Ingeniería Genética y Biotecnología, Ave 31, 158 and 190, PO Box 6162, Playa 10600, Havana, Cuba. yalena.amador@cigb.edu.cu
Key Words	Clinical trial; DNA vaccine; Enzyme-linked immunospot; Hepatitis C virus; Leukopenia
Core Tip	We assayed, for the first time, the concomitant administration of CIGB-230, a DNA-based therapeutic vaccine candidate against hepatitis C virus (HCV), and non-peginterferon-α (IFN-α) plus ribavirin therapy to chronic, treatment-naive, HCV genotype 1b infected patients. We showed that CIGB-230 enhanced the neutralizing antibody response and induced de novo proliferative and IFN-γ secretion responses in the context of antiviral therapy. The quality of the induced immune response depended on both the number of doses and the timing of administration in relation to the antiviral therapy. In particular, the increases in neutralizing antibodies and IFN-γ were associated with the sustained virological response.
Publish Date	2014-01-20 17:10
Citation	Amador-Canizares Y, Martínez-Donato G, álvarez-Lajonchere L, Vasallo C, et al. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. World J Gastroenterol 2014; 20(1): 148-162
URL	http://www.wjgnet.com/1007-9327/full/v20/i1/148.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i1.148

Full Article (PDF)	WJG-20-1.pdf
Full Article (Word)	WJG-20-1.doc
Manuscript File	2554-Review.doc
Answering Reviewers	2554-Answering reviewers.pdf
Copyright License Agreement	2554-Copyright assignment.pdf
Peer-review Report	2554-Peer review(s).docx
Scientific Editor Work List	2554-Scientific editor work list.doc